Stordahl Capital Management Inc. purchased a new position in Omeros Co. (NASDAQ:OMER – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 40,000 shares of the biopharmaceutical company’s stock, valued at approximately $395,000.
Other institutional investors and hedge funds also recently modified their holdings of the company. MML Investors Services LLC grew its holdings in shares of Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 3,000 shares in the last quarter. State Street Corp boosted its stake in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after buying an additional 3,839 shares during the period. HighTower Advisors LLC grew its holdings in shares of Omeros by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 4,000 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Omeros by 21.2% in the fourth quarter. SG Americas Securities LLC now owns 24,361 shares of the biopharmaceutical company’s stock worth $241,000 after acquiring an additional 4,257 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Omeros by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock worth $5,318,000 after acquiring an additional 6,839 shares in the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Friday, January 17th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a research report on Thursday, November 14th. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 price target on shares of Omeros in a research report on Thursday, January 16th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.50.
Omeros Stock Down 3.2 %
Shares of NASDAQ:OMER opened at $8.67 on Thursday. The stock’s 50-day moving average is $9.84 and its 200-day moving average is $6.27. Omeros Co. has a 52-week low of $2.61 and a 52-week high of $13.60.
Omeros Profile
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.
Featured Stories
- Five stocks we like better than Omeros
- Using the MarketBeat Dividend Tax Calculator
- Kimberly-Clark: A Regal Opportunity in This Dividend King
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 5 Stocks With Above-Market Yields Just Raised Payments Further
- 3 Healthcare Dividend Stocks to Buy
- Arista Networks’ Stock Plunge: Buying Opportunity for Investors?
Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Co. (NASDAQ:OMER – Free Report).
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.